Latest News

Unleashad

European_Commission.svg

TILT won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument. The grant will be used to perform a Phase 1 clinical trial with the company’s lead drug, TILT-123. Read the press release here.

Latest News

Upcoming Events

Please contact our business development team to meet us at the following events:

1-2nd March 2023
Zurich, Switzerland
14-15th March 2023
Helsinki, Finland
20-22nd March 2023
Basel, Switzerland
15–16th May 2023
Dublin, Ireland
16-20th May 2023
Los Angeles (CA), USA
2-6th June 2023
Chicago (IL), USA
5-8th June 2023
Boston (MA), USA
13-14th September 2023
Boston (MA), USA
20-24th October 2023
Madrid, Spain
29-30th November
Copenhagen, Denmark